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ARTICLE
Snail determines the therapeutic response to
mTOR kinase inhibitors by transcriptional
repression of 4E-BP1
Jun Wang1,2, Qing Ye1,2, Yanan Cao1,2, Yubin Guo1,3, Xiuping Huang1,3, Wenting Mi1,3, Side Liu3, Chi Wang1,4,
Hsin-Sheng Yang1,5, Binhua P. Zhou1,6, B. Mark Evers1,7 & Qing-Bai She 1,2
Loss of 4E-BP1 expression has been linked to cancer progression and resistance to mTOR
inhibitors, but the mechanism underlying 4E-BP1 downregulation in tumors remains unclear.
Here we identify Snail as a strong transcriptional repressor of 4E-BP1. We find that 4E-BP1
expression inversely correlates with Snail level in cancer cell lines and clinical specimens.
Snail binds to three E-boxes present in the human 4E-BP1 promoter to repress transcription of
4E-BP1. Ectopic expression of Snail in cancer cell lines lacking Snail profoundly represses 4E-
BP1 expression, promotes cap-dependent translation in polysomes, and reduces the anti-
proliferative effect of mTOR kinase inhibitors. Conversely, genetic and pharmacological
inhibition of Snail function restores 4E-BP1 expression and sensitizes cancer cells to mTOR
kinase inhibitors by enhancing 4E-BP1-mediated translation-repressive effect on cell pro-
liferation and tumor growth. Our study reveals a critical Snail-4E-BP1 signaling axis in
tumorigenesis, and provides a rationale for targeting Snail to improve mTOR-targeted
therapies.
DOI: 10.1038/s41467-017-02243-3 OPEN
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The kinase, mammalian target of rapamycin (mTOR),controls cell proliferation, survival, and metabolism byintegrating a variety of signals from growth factors and
nutrients1. The multiple functions of mTOR are exerted by the
formation of two distinct protein complexes, mTOR complex 1
(mTORC1) and mTOR complex 2 (mTORC2). mTORC1 reg-
ulates messenger RNA translation to promote protein synthesis
and cell proliferation by phosphorylating two primary down-
stream effectors, eukaryotic initiation factor 4E (eIF4E)-binding
protein 1 (4E-BP1) and 70 kDa ribosomal protein S6 kinase 1. 4E-
BP1 is a translational repressor, which prevents the assembly of
the eIF4F translation initiation complex by competing with eIF4G
for binding to eIF4E, a 5′ mRNA cap-binding subunit of the
eIF4F complex2. Phosphorylation of 4E-BP1 by mTORC1 results
in the release of eIF4E, thus increasing eIF4E availability for cap-
dependent mRNA translation3–5. The mTORC2 complex pre-
dominantly controls cell survival and cytoskeleton organization
by phosphorylating AKT and paxillin, among other proteins.
mTOR signaling is activated in the majority of cancers owing to
mutations in upstream signaling components including RAS,
PI3K, PTEN, TSC1, TSC2, and LKB11. Thus, mTOR signaling is
believed to be an essential component for tumor development
and progression, and targeting mTOR is thought to be a pro-
mising strategy for cancer therapy.
Rapamycin and related ‘rapalogs’ are allosteric inhibitors of
mTORC1, and were among the first mTOR-targeted therapeutics
in the treatment of solid tumors6. Rapalogs have shown some
success in specific tumor types and in patients with rare somatic
TSC mutations7, but their overall activity as a monotherapy is
limited6. This poor response might result from the weak inhibi-
tion of 4E-BP1 phosphorylation by rapalogs and induction of
AKT activation through loss of the mTORC1/S6K-dependent
negative feedback loops1,6,8. To overcome these issues, several
new ATP-competitive mTOR kinase inhibitors (mTORkis) such
as AZD80559 and INK12810, which inhibit both mTORC1 and
mTORC2, have been developed and are being evaluated in clin-
ical trials. Many of these small-molecule mTORkis profoundly
abrogate phosphorylation of both 4E-BP1 and AKT, and exhibit
superior anti-proliferative and anticancer activities compared
with rapamycin. Nonetheless, a number of recent studies,
including our own, demonstrate that deregulation of cap-
dependent translation by an incomplete inhibition of 4E-BP1
phosphorylation, reduction of 4E-BP1 expression, or upregula-
tion of eIF4E expression renders cancer cell resistance to
mTORkis11–16.
A growing body of evidence indicates that 4E-BP1 is a critical
effector of mTOR signaling through translational control of key
oncogenic mRNAs that encode proteins for cell-cycle progres-
sion, cell survival, angiogenesis, cancer progression, and metas-
tasis17. 4E-BP1 expression is regulated by both transcriptional
and posttranslational mechanisms17. Reduction of 4E-BP1
expression in cancer has been linked to malignant progression
and poor prognosis13,18. However, the molecular mechanism
underlying the decreased 4E-BP1 levels in cancer is poorly
understood. We recently showed that 4E-BP1 negatively regulates
cap-dependent translation of Snail, an important transcription
factor triggering epithelial–mesenchymal transition (EMT) and
promoting cancer invasion and metastasis14. Here we demon-
strate that Snail acts as a reciprocal feedback suppressor of 4E-
BP1 expression by blocking the transcription of the 4E-BP1 gene,
which mitigates the antitumor activities of mTORkis in cancer
cells with overexpression of Snail.
Results
4E-BP1 and Snail levels inversely correlate in cancer. In a
previous study14, we uncovered the interesting fact that knock-
down of Snail by small interfering RNAs (siRNAs) largely
increases 4E-BP1 expression in HCT116 colon cancer cells. As
Snail is a well-known transcriptional repressor capable of binding
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Fig. 1 4E-BP1 expression inversely correlates with Snail expression in cancer. a Cell lysates were prepared from the indicated cancer cell lines and analyzed
by western blotting for the indicated proteins. b, c A tissue array of 72 human colorectal cancer specimens was subjected to immunohistochemical staining
using antibodies against Snail (b, left) and 4E-BP1 (b, right). The immunoreactivity was scored blindly according to the value of immunoreaction intensity
(none= 0; weak= 1; intermediate= 2; and strong= 3) and the percentage of tumor cell staining (none= 0; < 10= 1; 10–50= 2; > 50%= 3). The intensity
and percentage values were added to provide a final immunoreactivity score ranging from 0 to 6. A score from 0 to 4 was defined as low protein
expression and a score of 5–6 indicates a high level of protein expression. Representative staining images are shown in b and the immunoreactivity scores
of the 72 specimens are summarized in a grid c that associates expression for both Snail and 4E-BP1. Statistical significance of the correlation between Snail
and 4E-BP1 expression was determine by the χ2-test with the p-value indicated. Scale bar, 50 µm
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and inhibiting promoter activity of many target genes such as
E-cadherin and phosphatase and tension homolog (PTEN)19–21,
we hypothesized that 4E-BP1 may be a transcriptional target of
Snail. We first performed western blot analysis on a panel of
breast (H1500, MCF7, T47D, ZR75-1, MDA-231, MDA-157, and
SUM149), colon (DLD-1, HCT15, HCT116, and SW480), and
lung (A549) cancer cell lines. The results of this analysis could be
split into two groups: low and high Snail protein expression
levels, and we found that Snail protein levels inversely correlated
with expression of 4E-BP1 (Fig. 1a). Consistent with previous
studies19, Snail expression was also inversely associated with E-
cadherin expression in all except the SUM149 cell line. Of note, as
compared with E-cadherin expression, 4E-BP1 expression was
not detectable in the Snail-overexpressing SUM 149 cells (Fig. 1a).
Using immunohistochemical staining, we expanded the exam-
ination of Snail and 4E-BP1 expressions in colorectal cancer
clinical specimens, and a significant inverse correlation was found
(Fig. 1b, c).
Snail selectively downregulates 4E-BP1 expression. The inverse
relationship between Snail and 4E-BP1 protein levels prompted
us to investigate the ability of Snail to regulate 4E-BP1 expression.
First, we expressed Snail in three cell lines that lack Snail protein
(HEK293, T47D, and MCF7). Ectopic expression of human Snail
almost completely suppressed 4E-BP1 protein expression in these
cell lines (Fig. 2a). Moreover, overexpression of Snail in HCT116
cells, which endogenously expresses Snail, further repressed 4E-
BP1 expression (Fig. 2a). Similar to the well-characterized
repression of E-cadherin mRNA expression by Snail, Snail-
expressing cells (T47D, MCF7, and HCT116) also showed a
dramatic reduction of 4E-BP1 mRNA expression (Fig. 2b). To
determine whether 4E-BP family members, 4E-BP2 and 4E-BP3,
are also regulated by Snail, we designed specific primer sequences
to selectively determine their mRNA expression. Interestingly, the
mRNA level between Snail-expressing and control cells for 4E-
BP2 or 4E-BP3 was not changed (Fig. 2b). On the other hand,
knockdown of Snail with stable expression of two different sets of
short hairpin RNAs (shRNAs) in three cancer cell lines expres-
sing high levels of Snail (HCT116, MDA-231, and SUM149)
resulted in a profound induction of 4E-BP1 expression at both the
protein and mRNA levels (Fig. 2c, d). E-cadherin mRNA
expression was also markedly upregulated, but the levels of 4E-
BP2 and 4E-BP3 remained unchanged in response to Snail
knockdown. Collectively, these data reveal that Snail selectively
downregulates 4E-BP1 gene expression.
To further validate the role of Snail in the regulation of 4E-BP1
expression, we generated Snail knockout (KO) HCT116 and
MDA-231 cells using the CRISPR-Cas9 nickase system22.
Sequencing confirmed that two types of frameshift indels were
created in the targeted region of Snail exon 1 in the KO cells, but
not in the wild-type (WT) cells (Supplementary Fig. 1a). In both
HCT116 and MDA-231 cell lines, disruption of Snail markedly
increased 4E-BP1 expression (Supplementary Fig. 1b). Impor-
tantly, re-expression of Snail in the two Snail KO-HCT116 or
SUM149
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Fig. 2 Snail represses 4E-BP1 expression at both the protein and mRNA levels. a HEK293, T47D, MCF7, and HCT116 cells with stable expression of Snail or
vector control were analyzed by western blotting for the indicated proteins. b mRNA expression of the indicated genes was analyzed by quantitative RT-
PCR in T47D, MCF7, and HCT116 cells with stable expression of Snail or vector control. The indicated gene expression was normalized against GAPDH and
presented as a percentage of the expression level found in vector control cells. c HCT116, MDA-231, and SUM149 cells with stable expression of two
different sets of Snail shRNAs (ShSnail_1 and ShSnail_2) or control shRNA (ShCtrl) were analyzed by western blotting for the indicated proteins. d mRNA
expression of the indicated genes was analyzed by quantitative RT-PCR in HCT116, MDA-231, and SUM149 cells with stable expression of ShSnail_1,
ShSnail_2, or ShCtrl. The indicated gene expression was normalized against GAPDH and presented as a fold increase over the expression level found in
ShCtrl cells. All graphic data are presented as mean± SEM (n= 3 technical replicates per condition). *P< 0.001 for Snail vs. vector or ShSnail vs. ShCtrl
using Student's t-test
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MDA-231 cell clones restored the ability of Snail to repress 4E-
BP1 expression (Supplementary Fig. 1c). Snail is highly expressed
in fibroblasts in association with loss of E-cadherin expression23.
Interestingly, silencing Snail using siRNAs in two Snail-
expressing normal human fetal lung fibroblasts (IMR-90 and
TIG1) also dramatically increased the expression levels of both
4E-BP1 and E-cadherin (Supplementary Fig. 2). Thus, these
results corroborate that Snail is a critical repressor of 4E-BP1
expression.
Snail directly represses 4E-BP1 promoter activity. To explore
the molecular mechanism by which Snail could repress the
transcription of 4E-BP1, we first analyzed the human 4E-BP1
genomic sequence and found that the 4E-BP1 promoter contains
three putative Snail-binding E-boxes24 (5′-CAGGTG-3′ or 5′-
CACCTG-3′) upstream of its transcription start site (Fig. 3a and
Supplementary Fig. 3a). We cloned a fragment of the human 4E-
BP1 promoter (position − 1,555/+ 233) containing the three E-
boxes and fused it to a firefly luciferase reporter. By transient
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Fig. 3 Snail represses 4E-BP1 promoter activity. a Schematic diagram of the human 4E-BP1 promoter-firefly luciferase construct (4E-BP1-Luc) showing
positions of the three potential Snail-binding E-boxes (E1, E2, and E3). Mutated (Mut) nucleotides in each E-box sequence are indicated with red
characters. b, c The indicated cell lines with expression b or knockdown c of Snail or their respective controls were co-transfected with human 4E-BP1-Luc
and an internal control Renilla-Luc. After 36 h, luciferase activities were measured and normalized. The results are expressed as a percentage of the activity
found in vector control cells b or as a fold increase over the Luc activity found in shRNA control (ShCtrl) cells c. d ChIP analysis of Snail-expressing HEK293
cell extracts using a specific antibody against Snail or an irrelevant IgG. Four sets of primers cover E1, E2, and E3 boxes and non-E-box region (NER) on the
4E-BP1 promoter, and a set of primers covers an E-box of the E-cadherin promoter as a positive control. e Enrichment levels for Snail or an irrelevant IgG at
four regions of 4E-BP1 promoter and an E-box region of E-cadherin promoter as shown in d are presented as a percentage of input. f ChIP analysis of DNA
from different cell lines using a specific antibody against Snail and the set 3 primers described in d. g Snail-expressing or vector control T47D cells were co-
transfected with pGL3-4E-BP1-Luc (WT, wild type) or the same plasmid containing mutations in different E-boxes together with an internal control Renilla-
Luc. Data are expressed as Luc activity in the presence of exogenous Snail as a percentage of the activity of the same reporter in vector control cells. All
graphic data are presented as mean± SEM (n= 3 technical replicates per condition). *P< 0.001 for Snail vs. vector or ShSnail vs. ShCtrl; #P< 0.001 for
each mutated E-box vs. WT; **P< 0.02 for the combination of mutated E-boxes vs. WT or each mutated E-box. Statistical significance was determine by
Student’s t-test
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transfection with this 4E-BP1 promoter reporter into T47D,
ZR75-1 and HCT116 cells that stably expressed either Snail or
vector control, we found that Snail expression significantly
repressed 4E-BP1 promoter activity in these cells (Fig. 3b).
Conversely, silencing Snail using shRNAs in HCT116, MDA-231
and SUM149 cells or disruption of Snail in HCT116 and MDA-
231 cells induced two to six fold increase in the 4E-BP1 promoter
activity (Fig. 3c and Supplementary Fig. 3b). To determine
whether Snail binds to regulatory regions of the 4E-BP1 pro-
moter, we performed chromatin immunoprecipitation (ChIP)
analysis in HEK293 cells expressing Snail using three sets of
primers; these covered E-box 1 (− 1,199/− 1,114), 2 (− 767/− 676),
and 3 (− 560/− 481) sequences of the 4E-BP1 gene, respectively
(Fig. 3d). Snail occupied all three E-box regions of the 4E-BP1
promoter (Fig. 3d), although the relative Snail occupancy was
greater at E-boxes 2 and 3 than E-box 1 (Fig. 3e). In contrast,
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Snail did not bind to the non-E-box region (− 384/− 228) of the
4E-BP1 promoter, but did bind to the E-box region of the
E-cadherin gene (Fig. 3d, e). Moreover, a subsequent ChIP
experiment using a panel of cell lines showed endogenous Snail
binding to the 4E-BP1 promoter in the cell lines that have high
Snail/low 4E-BP1 expression, but not in cell lines with low Snail/
high 4E-BP1 expression (Figs 1a and 3f). To further define the
putative E-box elements inside the human 4E-BP1 promoter that
are involved in repression by Snail, each E-box sequence was
mutated (Fig. 3a). We compared the ability of Snail to repress
different reporter constructs carrying each mutated E-box alone and
in combination in Snail-expressing T47D cells. These experiments
revealed that all three E-boxes were required for and cooperated in
the Snail-mediated 4E-BP1 repression (Fig. 3g). These data suggest
that Snail specifically and directly binds to the three E-boxes on the
human 4E-BP1 promoter to repress its transcription.
To test whether the direct regulation of 4E-BP1 by Snail is
conserved among mammals, we searched for the Snail-binding
E-box of the 4E-BP1 promoter from different species. Interest-
ingly, we found that the human Snail-binding E-boxes (5′-
CAGGTG-3′ or 5′-CACCTG-3′) and their surrounding sequences
are highly conserved among primate species, chimpanzee and
monkey (Supplementary Fig. 4a). The mouse and rat do not share
the exact human Snail-binding E-box sequences on their 4E-BP1
promoters, but the 5′-CACTTG-3′ or 5′-CAAGTG-3′ core, which
is a relatively strong Snail-binding motif24, was found on their
4E-BP1 promoters and is highly conserved between mouse and
rat (Supplementary Fig. 4b). One E-box sequence (position − 75/
− 70) was identified immediately upstream of the mouse 4E-BP1
transcriptional start site and two additional E-boxes were
identified at positions at − 929/− 924 and − 940/− 935 from the
transcription start site (Supplementary Fig. 4b). We tested the
ability of Snail to repress the isolated mouse 4E-BP1 promoter
(position − 1,430/+ 80) by luciferase reporter assay. Expression of
either human or mouse Snail effectively repressed mouse 4E-BP1
promoter activity, as well as its expression at both the protein and
mRNA levels in NMuMG mouse mammary epithelial cells and in
4T1 mouse mammary carcinoma cells (Supplementary Fig. 4c–e).
Conversely, knockdown of mouse Snail expression in NIH3T3
fibroblasts markedly upregulated 4E-BP1 protein and mRNA
expression (Supplementary Fig. 4f, g). As a positive control,
mouse E-cadherin expression was also negatively regulated by
Snail expression (Supplementary Fig. 4d–g). Similarly, the canine
4E-BP1 promoter also contains three putative Snail-binding E-
boxes upstream of its transcription start site (Supplementary
Fig. 5a). Ectopic expression of human Snail also profoundly
suppressed 4E-BP1 promoter activity and its expression in
Madin–Darby canine kidney (MDCK) cells (Supplementary
Fig. 5b–d). Taken together, these results indicate that 4E-BP1 is
a conserved transcriptional target of Snail.
Slug and Zeb1 are two transcriptional factors that mimic Snail
repression of E-cadherin through binding to the same E-box
elements25,26, whereas the Twist1 transcriptional factor indirectly
represses E-cadherin expression through binding to a different E-
box motif27. To test whether these EMT-inducing transcriptional
factors also regulate 4E-BP1 expression, Slug, Zeb1, and Twist1
genes were transiently transfected in T47D cells that lack
expression of these transcriptional factors (Supplementary
Fig. 6a). Similar to Snail expression, Slug expression strongly
repressed 4E-BP1 promoter activity and its mRNA and protein
expression, whereas expression of Zeb1 or Twist1 did not
significantly inhibit 4E-BP1 expression but did markedly repress
E-cadherin expression (Supplementary Fig. 6b-d). Importantly,
knockdown of Slug in MDA-231 and MDA-157 breast cancer cell
lines that express high levels of Slug, by either transient
transfection with siRNAs or stable expression of specific shRNAs,
provided results similar to the knockdown of Snail: a profound
increase in 4E-BP1 expression at both the mRNA and protein
levels (Supplementary Fig. 6a, e–j). Silencing Zeb1 provided a
dramatic increase in E-cadherin expression but had no effect on
4E-BP1 expression in both cell lines (Supplementary Fig. 6e, f, i, j).
Moreover, silencing Twist1 also showed no effect on 4E-BP1
expression but significantly upregulated E-cadherin expression in the
Twist1-overexpressing MDA-157 cells (Supplementary Fig. 6a, i, j).
These data suggest that the Snail family member, Slug, may also
function as a strong transcriptional repressor of 4E-BP1.
Snail modulates mTOR/4E-BP1-mediated translation. Loss of
4E-BP1 expression activates cap-dependent translation and cau-
ses cancer cell resistance to mTORkis12–14. Therefore, we inves-
tigated whether Snail regulates cap-dependent translation by
repressing 4E-BP1 and thereby alters the ability of mTORkis to
effect translation. Using a dual luciferase reporter system that
monitors the ratio between cap-dependent and -independent
translation initiation28,29, we found that expression of Snail in
MCF7 and T47D cells significantly increased the cap-dependent
translation rate but had no effect on initiation at internal ribo-
some entry sites (IRES)-driven cap-independent translation; in
addition, Snail expression largely attenuated the cap-dependent
translation inhibition induced by mTORkis, AZD8055, and
INK128 (Fig. 4a and Supplementary Fig. 7a). Conversely,
knockdown of Snail in HCT116 and MDA-231 cells repressed
cap-dependent but not cap-independent translation, and the
inhibitory effect on cap-dependent translation was enhanced by
AZD8055 or INK128 (Fig. 4b and Supplementary Fig. 7b). Most
importantly, with respect to cap-dependent translation, depletion
of 4E-BP1 completely reversed the inhibitory effects of Snail
knockdown or KO alone, and in combination with INK128 in
HCT116 cells (Fig. 4c and Supplementary Fig. 7c, d), suggesting
Fig. 4 Snail influences mTOR/4E-BP1-controlled translation and polysome formation. a, b Snail-expressing a or -knockdown b cells and their respective
controls were transfected with a bicistronic luciferase reporter that detects cap-dependent translation of the Renilla luciferase gene and cap-independent
translation of the firefly luciferase gene. After 24 h, cells were treated with mTOR kinase inhibitors AZD8055 (100 nM), INK128 (100 nM), or DMSO for 12
h, followed by measurement of luciferase activities. The ratio of Renilla/firefly luciferase activities was calculated and presented as a percentage of the cap-
dependent translation activity found in the DMSO-treated control cells. c Cap-dependent translation analysis of Snail wild-type (WT) and knockout (KO)
HCT116 cells expressing 4E-BP1 shRNA or control shRNA treated with 100 nM INK128 for 12 h. d, e Snail-expressing T47D cells d or Snail-knockdown
HCT116 cells e and their respective controls were treated with 100 nM AZD8055, 100 nM INK128, or DMSO for 12 h. Cell lysates were precipitated with
m7GTP sepharose beads or immunoprecipitated with eIF4E antibody followed by western blot analysis for the indicated proteins. f–i Snail-expressing or
vector control MCF7 cells f, g and Snail WT or KO HCT116 cells h, i were treated with 100 nM INK128 or DMSO as control for 12 h, followed by polysome
analysis. The vertical blue line separates the polysomal (P) and monosomal (M) fractions. The P/M ratio, an index of translational efficiency, was
calculated by comparing areas under the polysome and monosome peaks using NIH image J. The results are expressed as a percentage of the P/M ratio
relative to the DMSO-treated vector g or Snail WT i controls. j, k Nascent protein synthesis was measured for Snail-expressing or vector control T47D cells
j and Snail WT or KO HCT116 cells k treated with 100 nM INK128 or DMSO for 12 h. The results are expressed as a percentage of methionine analog
incorporation relative to the DMSO-treated control cells. All graphic data are presented as mean± SEM (n= 3 technical replicates per condition). *P<
0.01; #P< 0.001; NS, not significant using Student’s t-test
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that Snail modulation of mTOR-regulated cap-dependent trans-
lation is mediated through 4E-BP1.
Although silencing Snail increased 4E-BP1 expression (Fig. 2c),
it is likely to be that a large fraction of 4E-BP1 in cancer cells is
hyperphosphorylated by oncogenic PI3K/AKT and RAS/ERK
signaling17,29; the ability of 4E-BP1 to repress cap-dependent
translation is compromised when in the phosphorylated
state3,5,17,29,30. Dephosphorylated 4E-BP1 by mTOR inhibition
competes with eIF4G to bind eIF4E and prevents formation of
eIF4F complex (eF4E, eIF4A, and eIF4G), thus inhibiting eIF4E-
initiated cap-dependent translation3,5,17. To examine whether the
effect of Snail expression on mTOR-regulated cap-dependent
translation is associated with the level of 4E-BP1 bound to eIF4E,
we first examined the eIF4E-mRNA cap-binding capacity of 4E-
BP1 using m7GTP Sepharose beads, which mimics the 5′-mRNA
cap to precipitate cap-interacting proteins. As shown in Fig. 4d, e
Snail expression in T47D cells profoundly decreased the binding
of 4E-BP1 to eIF4E induced by either AZD8055 or INK128,
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whereas silencing Snail in HCT116 cells had the opposite effect,
with an increased 4E-BP1-eIF4E interaction when cells were
treated with either mTORki. This observation in response to Snail
expression or knockdown was confirmed by co-immunopreci-
pitation for the 4E-BP1-eIF4E interaction (Fig. 4d, e). Further-
more, the decreased 4E-BP1-eIF4E interaction in Snail-expressing
T47D cells treated with mTORkis was accompanied by an
increased formation of eIF4F complex as noted by increased
levels of eIF4G and eIF4A bound to eIF4E (Fig. 4d). Conversely,
the increased 4E-BP1-eIF4E interaction in Snail-depleted
HCT116 cells treated with mTORkis was accompanied by
decreased formation of the eIF4F complex (Fig. 4e). Together,
these data demonstrate that Snail-mediated repression of 4E-BP1
promotes cap-dependent translation and relieves the inhibitory
effect of mTORkis on the translation.
mRNA is actively translated in polysomes and changes in
overall translational efficiency are reflected by the changes in the
ratio of polysomal (P) to monosomal (M) fractions28,29.
Polysome profile analysis showed that Snail expression in
MCF7 cells increased the P/M ratio (34%) compared with cells
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expressing vector control (Fig. 4f, g). Treatment with INK128
decreased polysome assembly with a 30% reduction in the P/M
ratio of MCF7-vector cells, but this reduction was almost
completely abrogated by expression of Snail (Fig. 4f, g). By
contrast, both Snail KO and treatment with INK128 reduced the
P/M ratio (20–22%) in HCT116 cells (Fig. 4h, i). However, Snail
KO in combination with INK128 further impaired polysome
assembly by reducing the P/M ratio up to 41%. These effects were
corroborated by measuring nascent protein synthesis (Fig. 4j, k).
Overexpression of Snail in T47D cells increased protein synthesis
and largely prevented the inhibitory effect of INK128 on protein
synthesis (Fig. 4j), whereas Snail KO in combination with
INK128 in HCT116 cells resulted in a more marked suppression
of protein synthesis (62%) than either Snail KO or INK128
treatment alone (35–38%) (Fig. 4k). In total, these data indicate
that Snail promotes recruitment of capping mRNAs to eIF4F for
their active translation in polysomes, and that mTOR-regulated
cap-dependent translation rate is altered by Snail-mediated
repression of 4E-BP1.
Snail reduces the anti-proliferative effect of mTORkis. We next
examined whether Snail confers an increased resistance to
mTORkis through decreased 4E-BP1 expression. We compared
the effect of mTORkis on growth in cancer cells with low and
high levels of Snail. As compared with cancer cells with low Snail/
high 4E-BP1 expression (MCF7, T47D, ZR75-1, and DLD-1,
Fig. 1a), cancer cells expressing high Snail/low 4E-BP1 (MDA-
231, MDA-157, SUM149, and HCT116, Fig. 1a) were significantly
less sensitive to both AZD8055 and INK128, with a five to
seven fold increase in half-maximal growth inhibitory con-
centration values (Fig. 5a, b). Notably, ectopic expression of Snail
in MCF7 and T47D cells significantly increased cell growth
(Fig. 5c). Treatment with either AZD8055 or INK128 profoundly
inhibited growth of these two cell lines, but this suppression was
largely alleviated by Snail expression (Fig. 5c). By contrast,
silencing Snail using shRNAs in HCT116, MDA-231, and
SUM149 cells inhibited their growth and markedly augmented
the sensitivity of these cells to both AZD8055 and INK128
(Fig. 5d). Similar results were observed by disruption of Snail in
HCT116 and MDA-231 cells (Supplementary Fig. 8a). A long-
term colony formation assay that incorporates chronic treatment
with AZD8055 or INK128 in Snail-depleted HCT116 cells con-
firmed the sensitization of these cells to mTORkis (Supplemen-
tary Fig. 8b). Cell cycle analysis revealed that Snail expression in
T47D cells significantly promoted G1-S progression and alle-
viated the mTORkis-induced inhibition of G1-S progression,
whereas silencing Snail in HCT116 cells suppressed G1-S pro-
gression and further enhanced inhibition of G1-S progression by
mTORkis but did not exert a major effect on cell survival (Fig. 5e,
f). These results imply that Snail alters the sensitivity of cancer
cells to mTORkis largely through a regulation of cell cycle
progression.
To evaluate whether the Snail-regulated 4E-BP1 level controls
the sensitivity of cells to mTORkis, we first stably expressed
exogenous 4E-BP1 to rescue the loss of 4E-BP1 in Snail-
expressing MCF7 and T47D cells (Figs 2a and 6a). Interestingly,
we found that restoration of 4E-BP1 suppressed growth in Snail-
expressing MCF7 or T47D cells and sensitized these cells to
AZD8055 or INK128 treatment (Fig. 6b). Next, silencing 4E-BP1
to reverse the increased 4E-BP1 level induced by Snail KO in
HCT116 cells, largely attenuated cell growth inhibition by Snail
KO alone or in combination with INK128 (Fig. 6c, g). These data
reveal a critical role for 4E-BP1 in the modulation of cell
sensitivity to mTORkis by Snail.
As Snail has been reported to activate AKT by transcriptional
repression of PTEN21, we tested whether PTEN/AKT signaling is
also regulated by Snail and confers increased resistance to
mTORkis in our tested cell lines. Among the three cell lines
(T47D, MCF7, and HCT116) expressing exogenous Snail as
shown in Fig. 2a, Snail expression only slightly repressed PTEN
expression, coincident with enhanced activation of AKT in T47D
cells but not in the two other cell lines (Supplementary Fig. 9a, b).
Treatment with either AZD8055 or INK128, at the same
concentration (100 nM) used to evaluate cell growth, effectively
inhibited phosphorylation of mTOR substrates including AKT,
S6K, and 4E-BP1, as well as the S6K substrate, S6 ribosomal
protein, in both Snail-expressing or vector control T47D cells
(Fig. 6d). Furthermore, Snail-expressing T47D cells with
decreased 4E-BP1 level (Figs 2a and 6d) were significantly less
sensitive to mTORkis compared with the vector control cells
(Fig. 5c). In addition, silencing Snail in HCT116, MDA-231, and
SUM149 cells (Fig. 2c) did not affect PTEN expression or AKT/
S6K phosphorylation (Supplementary Fig. 9c,d). It is important to
note that SUM149 cells have a naturally occurring PTEN loss
associated with constitutive activation of AKT31 (Supplementary
Fig. 9c) and silencing Snail still sensitized SUM149 cells to
mTORkis (Fig. 5d), suggesting that the increased resistance to
mTORkis by Snail expression is independent of AKT activation.
This notion was supported when overexpression of AKT1 in
Snail-depleted HCT116 cells showed no significant change in
growth inhibition by Snail KO alone or in combination with
INK128 (Fig. 6e, f).
The G1-phase promoters, D-cyclins, are regulated by cap-
dependent translation12,32,33. We found that the expression of
cyclins D1 and D3 but not cyclin D2 was downregulated in Snail
KO HCT116 cells (Fig. 6g). It has been shown that Snail can
transcriptionally repress cyclin D2 expression in MDCK cells34.
Consistent with this finding, we observed suppression of cyclin
D2 and other Snail-repressed genes, including E-cadherin and
PTEN, in MDCK cells when expressing Snail using our Snail
construct35 (Supplementary Fig. 5c, d). However, no change in
cyclin D2 expression was found in Snail-expressing or -knock-
down cell lines used in this study (Supplementary Fig. 9a, c).
Treatment with INK128 in HCT116 cells downregulated Snail
expression (Fig. 6g), which is likely suppressed by depho-
sphorylated 4E-BP1 in the cap-dependent translation level as
reported previously14. However, downregulation of Snail did not
result in a significant change in 4E-BP1 levels (Fig. 6g), which
may have occurred because the levels of Snail bound to the 4E-
BP1 promoter were not affected by INK128 treatment (Supple-
mentary Fig. 10). Nevertheless, treatment of HCT116 cells with
INK128 inhibited the expression of all D-cyclins, but the
downregulation of cyclins D1 and D3 by INK128 was more
pronounced in Snail KO HCT116 cells (Fig. 6g), and these
downregulations were not associated with changes in their
transcript levels (Fig. 6h). Notably, the suppression of cyclins
D1 and D3 was associated with increased levels of total and
dephosphorylated 4E-BP1 in Snail-depleted cells, and their
suppression was almost completely eliminated by silencing 4E-
BP1 (Fig. 6g). Taken together, these results support a model
whereby Snail-mediated repression of 4E-BP1 mitigates the anti-
proliferative effect of mTORkis by continuous translation of cell
cycle promoters such as cyclins D1 and D3.
Targeting Snail enhances mTORki therapy in vivo. To explore
whether Snail-mediated 4E-BP1 repression also reduces the
therapeutic response to mTORkis in vivo, nude mice bearing
established Snail WT or Snail KO HCT116 xenograft tumors
were treated with INK128 or vehicle control. Preliminary data
showed that treatment with 1.5 mg kg−1 INK128 effectively
inhibited phosphorylation of the mTORC1 substrate 4E-BP1 and
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the mTORC2 substrate AKT for up to 8 h; however, phosphor-
ylation rebounded by 12 h after treatment (Supplementary
Fig. 11a). To sustain inhibition of mTOR downstream targets, we
treated mice with 1.5 mg kg−1 INK128 twice a day. Mice treated
with this regimen for 5 consecutive days/week for 3 weeks
demonstrated no gross toxicity or significant weight loss (Sup-
plementary Fig. 11b). Chronic treatment with INK128 slowed
tumor growth in mice with Snail WT HCT116 xenografts,
0
250
500
750
1,000
1,250
1,500
1,750
2,000
0 2 4 6 8 10 12 14 16 18 20
Days
HCT116-Snail WT
HCT116-Snail WT + INK128
HCT116-Snail KO
HCT116-Snail KO + INK128
* ** ***
Snail WT Snail KO
0.0
0.5
1.0
1.5
2.0
2.5
3.0
T
um
or
 w
ei
gh
t (
g)
p = 0.0022
p = 0.0129
p = 0.0043
0.0
0.5
1.0
1.5
2.0
HCT116 MDA-231
Vor 0 μM
Vor 1 μM
Vor 5 μM
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4E-BP1 E-cadherin
Vor 0 μM
Vor 1 μM
Vor 5 μM
#
0
200
400
600
800
1,000
1,200
1,400
1,600
1,800
0 5 10 15 20 25
Control
Vor
INK128
Combination
Days
##
#
#
#
#
#
#
#
##
0.0
0.5
1.0
1.5
2.0
2.5
Vector Snail
DMSO
Vor
#
#
Cyclin D1
Snail
Control INK128 Control INK128
Snail WT Snail KO
Cyclin D3
37
15
15
25
25
25
Vor (μM) 0 1 5
37
100
15
p-4E-BP1 (T37/46)
4E-BP1
β-actin
4E
-B
P
1 
pr
om
ot
er
 a
ct
iv
ity
 (
fo
ld
)
4E
-B
P
1 
pr
om
ot
er
 a
ct
iv
ity
 (
fo
ld
)
m
R
N
A
 e
xp
re
ss
io
n 
(f
ol
d)
β-actin
E-cadherin
4E-BP1
T
um
or
 v
ol
um
e 
(m
m
3 )
 
T
um
or
 v
ol
um
e 
(m
m
3 )
Control INK128 Control INK128
a b
c d e
f g h
Fig. 7 Co-targeting Snail and mTOR profoundly suppresses tumor growth in vivo. a Mice bearing HCT116-Snail WT or KO xenograft tumors were treated
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indicated proteins. d, e 4E-BP1 promoter activity was analyzed in T47D cells with stable expression of Snail or vector control d, and in HCT116 and MDA-
231 cells e that were treated with vorinostat (Vor) for 12 h. f, g HCT116 cells were treated with vorinostat for 12 h f or 24 h g, followed by quantitative RT-
PCR analysis for mRNA expression of 4E-BP1 and E-cadherin relative to the levels found in DMSO-treated control cells f, or by western blot analysis for the
indicated proteins g. All graphic data are presented as mean± SEM (n= 3 technical replicates per condition). #P< 0.001 using Student’s t-test. h Mice
bearing HCT116 xenografts were treated with vorinostat (50mg kg−1), INK128 (1.5 mg kg−1), the combination of both drugs, or vehicle control once daily for
5 consecutive days each week. The results are presented as the mean tumor volume± SEM (n= 6 mice per group). ##P< 0.001 for combination of
vorinostat and INK128 vs. vorinostat, INK128, or control using Student’s t-test
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whereas Snail KO alone provided a modest antitumor effect
(Fig. 7a). However, INK128 dramatically suppressed growth in
Snail KO-HCT116 xenografts (Fig. 7a, b). The marked growth
suppression in vivo was associated with a pronounced increase in
the level of the total and dephosphorylated 4E-BP1, as well as a
dramatic decrease in the levels of cyclins D1 and D3 (Fig. 7c).
These data recapitulate the increased resistance to mTORki by
Snail expression seen in vitro.
It is known that Snail requires histone deacetylase 1 (HDAC1)/
HDAC2 activities to repress the E-cadherin promoter36. To
determine whether HDAC also functions as a co-repressor of
Snail in repression of 4E-BP1, we used an Food and Drug
Administration-approved pan-HDAC inhibitor, vorinostat37, to
test the potential effects of this inhibitor on modulation of
4E-BP1 expression and efficacy of mTORkis. First, we analyzed
the effects of vorinostat on Snail-mediated repression of 4E-BP1
promoter activity. Similar to the data shown in Fig. 3b, ectopic
expression of Snail in T47D cells reduced activity of the 4E-BP1
promoter to 30%, but this repression was totally eliminated by
treatment with vorinostat (Fig. 7d). Furthermore, vorinostat
treatment also significantly increased 4E-BP1 promoter activity in
both HCT116 and MDA-231 cells, which express endogenous
Snail (Fig. 7e). The increased promoter activity of 4E-BP1 was
corroborated by increased 4E-BP1 transcripts and protein levels
after vorinostat treatment in HCT116 cells (Fig. 7f, g). Consistent
with the previous study36, vorinostat treatment also markedly
increased E-cadherin transcripts in HCT116 cells (Fig. 7f). These
results strongly suggest that HDAC activity is also required for
efficient suppression of the 4E-BP1 promoter. Next, we explored
whether HDAC inhibition by vorinostat could mimic genetic
depletion of Snail to improve the therapeutic effect of mTORkis.
In the mouse model of HCT116 xenograft tumors with high
Snail/low 4E-BP1 levels, treatment with either vorinostat (50 mg
kg−1) or INK128 (1.5 mg kg−1) modestly decreased tumor size
(Fig. 7h). However, vorinostat in combination with INK128
almost completely suppressed tumor growth with only marginal
weight loss (e.g., < 10%) in mice (Fig. 7h and Supplementary
Fig. 11c). These findings indicate that HDAC inhibitors greatly
enhance the antitumor effect of mTORkis, suggesting that
combined inhibition of HDAC and mTOR may be an effective
therapeutic strategy in cancers that overexpress Snail with
decreased 4E-BP1 expression.
Discussion
Snail is a key transcriptional factor with a well-characterized
function in promoting EMT, cancer cell invasion, and metas-
tasis38,39. Beyond EMT and tumor invasiveness, Snail and other
EMT-inducing transcription factors cooperate with oncogenes in
malignant transformation, regulate cancer cell stemness and dif-
ferentiation, contribute to cancer cell survival and metabolic
reprogramming, and impart resistance to chemotherapy35,40–42.
In this study, we uncover a novel function of Snail in mTOR/4E-
BP1-mediated translational control of tumorigenesis. We identi-
fied 4E-BP1 as a conserved transcriptional target of Snail in
mammals. We show that Snail represses 4E-BP1 expression to
promote the recruitment of capping mRNAs and ribosomal
subunits to the eIF4F translation initiation complex for active
translation in polysomes. Targeted inhibition of Snail activity
increases 4E-BP1 levels, which is required to enhance the sensi-
tization of cancer cells to mTOR kinase inhibitors. Our work
suggests that expression of Snail with a concomitant reduction of
4E-BP1 accounts for the limited efficacy of mTOR inhibitors in
cancer therapy (Fig. 8).
Our study provides several insights into the biology and
therapeutic relevance of Snail in the translational control of
tumor progression. First, our study reveals Snail as a positive
regulator of cap-dependent translation via repression of 4E-BP1,
suggesting that a Snail-specific translational program exists dur-
ing malignant transformation, EMT, and tumor progression. We
previously demonstrated that loss of 4E-BP1 induces EMT,
increases breast and colorectal cancer cell motility and invasive-
ness, and promotes metastasis by upregulation of Snail expression
in a cap-dependent translational manner14. Loss of 4E-BP1 can
result in an increased level of free eIF4E and phosphorylated
eIF4E to promote activation of cap-dependent translation13,43.
Similar to 4E-BP1 loss, eIF4E phosphorylation also promotes
EMT and metastasis by a translational increase of Snail protein44.
Our present data showed that Snail acts as a reciprocal feedback
repressor of 4E-BP1 to promote eIF4E-initiated capping mRNA
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Fig. 8 Snail modulates tumorigenesis and mTOR-targeted therapy by repression of 4E-BP1. Snail blocks 4E-BP1 gene transcription by binding to the
sequences of three E-boxes within the 4E-BP1 promoter, which, in turn, promotes eIF4E-initiated cap-dependent translation of Snail itself and cyclins D1/D3
for cell proliferation, and reduces the therapeutic efficacy of mTOR kinase inhibitors. Genetic depletion of Snail or pharmacological inhibition of Snail co-
repressor HDAC activity by vorinostat increases non-phosphorylated 4E-BP1 levels upon treatment with mTOR kinase inhibitors, which effectively
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translation and protein synthesis. Together, these results suggest
the existence of a positive feedback loop for continuous transla-
tion of Snail through repression of 4E-BP1 (Fig. 8). This positive
feedback loop might be required to maintain Snail expression to
transcriptionally but also translationally regulate expression of a
variety of gene sets responsible for the malignant transformation,
EMT induction, and metastasis. Whether Snail transcriptionally
and translationally regulates genes through a differential or
cooperative manner to alter cell plasticity for tumor progression
is likely to be complex and a matter for further investigation.
Moreover, our study found that the Snail family member, Slug,
also represses 4E-BP1 promoter activity and its expression, sug-
gesting that Slug may have secondary effect on cap-dependent
translation. Whether tumors with co-expression of Snail and Slug
require both proteins to additively initiate a cap-dependent
translation program during EMT and cancer development is
another question that remains to be determined.
Second, our study reveals Snail as an important determinant of
cancer cell sensitivity to mTOR inhibitors. Deregulation of cap-
dependent translation by mTOR-mediated phosphorylation of
4E-BP1 plays an important role in cancer progression17,29,30,45.
Thus, the use of mTORkis to inhibit 4E-BP1 phosphorylation
presents a promising strategy for cancer therapy. However, loss of
4E-BP1 expression with an increase in free eIF4E, rather than the
phosphorylation status of 4E-BP1, is considered to be a primary
determinant for cancer cell resistance to mTORkis12,13. Here we
identified Snail as a strong transcriptional repressor of 4E-BP1,
comparable to the effect of this repressor on E-cadherin expres-
sion. Our study demonstrates that the Snail-regulated 4E-BP1
level is a critical determinant of the anti-proliferative effects of
mTORkis through cap-dependent translational control of cyclins
D1 and D3 expression, and independent of AKT/S6K activation.
Our findings are consistent with several studies showing a posi-
tive role for Snail in cell proliferation by using a Snail transgenic
mouse skin model, expression or disruption of Snail in the
Drosophila ovarian model, and the PTEN-deficient glioblastoma
cells with knockdown of Snail expression46–49. However, others
reported opposite results that ectopic expression of Snail in the
canine normal epithelial MDCK cell line using a single cell clone
undergoing EMT could induce G1 arrest and resistance to
apoptosis by transcriptional repression of cyclin D2 and PTEN
expression21,34. Distinct from these reports21,34, we utilized a
population pool of the stable Snail-expressing cells in which Snail
expression may not be high enough to induce a complete EMT.
Indeed, using individual clones with different expression levels of
Snail in MDCK cells, we were able to reproduce their findings21,34
and found that high levels of Snail expression is required to
maximally repress expression of E-cadherin, cyclin D2, and
PTEN; induce a complete EMT; inhibit cell cycle progression and
proliferation; and render cell resistance to serum deprivation-
induced apoptosis (Supplementary Fig. 12a–g). Nevertheless, it is
noteworthy that 4E-BP1 expression in MDCK cells could be
effectively inhibited even at low to medium Snail expression
levels. In addition, these cells showed a partial EMT with no or
weak inhibition of expression of E-cadherin, cyclin D2, and
PTEN, but significantly increased cell proliferation and G1/S
progression, and were resistant to apoptosis (Supplementary
Fig. 12a–g). Similar results were observed in the mixed stable
Snail-expressing MDCK cell populations that showed a moderate
Snail expression level and relieved the anti-proliferative effect of
mTORkis (Supplementary Fig. 12h–j). Thus, the discordant Snail-
effect on cell proliferation and survival is probably associated with
diverse effects in the cell population expressing different levels of
Snail with variable EMT status and the type of cell or tissue and
species used. Another possibility is that in cancer cells, Snail
cooperates with other oncogenic signaling molecules, such as
mTOR, to maximally downregulate and inhibit their common
target, 4E-BP1, as shown here, to promote cell proliferation and
tumor progression by translational regulation of cyclins D1 and
D3 expression, and other potential targets. Together, these pro-
cesses allow cancer cells to escape mTOR-targeted therapies.
Third, our study strongly suggests that inhibition of Snail
activity could largely improve therapeutic efficacy of mTORkis in
cancers with low 4E-BP1 levels. Overexpression of Snail is fre-
quently observed in advanced carcinomas including breast and
colorectal cancers39,50,51. Our discovery of Snail as an important
modulator of 4E-BP1 expression and cancer cell sensitivity to
mTORkis suggests that the limited preclinical and clinical effi-
cacies of mTOR inhibition in breast, colorectal and other can-
cers52 may be attributed, in part, to the frequent genetic gains by
Snail associated with decreased expression of 4E-BP1. Our find-
ings indicate that Snail expression may serve as a predictive
marker for mTOR-targeted therapies in cancer. Extensive evi-
dence indicates that Snail is an attractive therapeutic target; yet,
there are no small molecules to inhibit Snail’s functions. As Snail
is required to recruit multiple chromatin enzymes for its tran-
scriptional repressive function53,54, targeting these epigenetic
regulators such as HDAC could be an alternative approach to
inhibit Snail activity. In this study, we found that, similar to
genetic depletion of Snail, pharmacological inhibition of HDAC
activity significantly repressed Snail activity by inducing 4E-BP1
expression, and co-targeting HDAC and mTOR resulted in a
marked suppression of tumor growth. Several recent studies55–57
also show that the combination of mTOR and HDAC inhibitors
exert a synergistic antitumor activity in a large panel of human
cancer cell lines, and the patient-derived xenograft and transgenic
mouse models. Interestingly, the synergistic growth inhibiting
consequence of combined mTOR/HDAC inhibition is likely
attributed to their mechanistic convergences on the mTOR/4E-
BP1 signaling axis and impaired polysome formation56. This
situation is similar to our findings obtained with Snail depletion
in combination with mTORkis. Given that multiple clinical trials
involving mTOR inhibitors as monotherapy or in combination
with HDAC inhibitors are being tested in advanced cancers
(NCT01058707, NCT02719691, NCT01087554, and
NCT00918333), our findings suggest that incorporating the
analysis of Snail and 4E-BP1 expression in primary tumors may
help to prospectively identify resistance to mTOR inhibitors in
the clinic studies.
Methods
Cell culture. Human breast (H1500, MCF7, T47D, ZR75-1, MDA-231, and MDA-
157), colon (HCT116, DLD-1, HCT15, and SW480), and lung (A549) cancer cell
lines, mouse NMuMG, 4T1 and NIH3T3 cell lines, and the MDCK cell line were
obtained from the American Type Culture Collection (ATCC, Manassas, VA) and
cultured in the appropriate medium with supplements as recommended by ATCC.
The SUM149 human breast cancer cell line was obtained from Asterand (Detroit,
MI) and cultured in Ham’s F-12 supplemented with 5% fetal bovine serum (FBS),
5 µg ml−1 insulin, and 1 µg ml−1 hydrocortisone. The IMR-90 and TIG-1 normal
human fetal lung fibroblasts were obtained from Coriell Institute for Medical
Research (Camden, NJ) and cultured in Eagle’s minimum essential medium sup-
plemented with 15% FBS. All cell lines were tested for mycoplasma contamination
via PCR (e-Myco Plus kit; iNtRON Biotechnology, Kirkland, WA) and were found
to be negative. In addition, all cell lines are routinely checked for morphologic and
growth changes, to probe for cross-contamination or genetically drift. If present,
cell lines were re-authenticated using the short tandem repeat profiling service by
ATCC.
Plasmids and reagents. The pLenti6.3-human Snail and Twist1 plasmids were
generated as described previously35,58. Human Slug and Zeb1 were also cloned into
the same pLenti6.3 lentivirus expression vector (Invitrogen, Grand Island, NY). To
establish stable transfectants with specific protein expression, cells were infected
with lentivirus using the indicated pLenti6.3 constructs followed by selection with
puromycin (2 µg ml−1) for 7–10 days as described previously30. The human 4E-BP1
promoter (positions − 1,555/+233) and mouse 4E-BP1 promoter (positions −
1,430/+80) were amplified from HCT116 and NIH3T3 cell genomic DNAs,
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respectively, and then cloned into the pGL3 basic reporter vector that contains
firefly luciferase (Promega, Madison, WI). The mutant reporter constructs that
carry the 4E-BP1 promoter with combinations of the three mutated E-boxes (see
Fig. 3a) were generated using the QuikChange XLII site-directed mutagenesis kit
(Stratagene, La Jolla, CA). The primers used are listed in Supplementary Table 1.
All sequences were verified by automated DNA sequencing. The pBabe-4E-BP1
plasmid with hygromycin resistance was generated as described previously14,29.
The pcDNA3-HA-AKT1 plasmid (73408) and p3xFLAG-mSnail plasmid (34583)
were purchased from Addgene (Cambridge, MA). AZD8055 and INK128 were
obtained from Selleckchem (Houston, TX) and Active Biochem (Maplewood, NJ),
respectively. Vorinostat was purchased from MedChem Express (Monmouth
Junction, NJ).
Gene silencing by siRNA and shRNA. Smart pool siRNA against human Snail (L-
010847), Slug (L-017386), Twist1 (L-006434), Zeb1 (L-006564), 4E-BP1 (L-
003005), or non-targeting control siRNA pool (D-001810-10) was obtained from
Dharmacon (Chicago, IL). Cells were transfected with 20 nM siRNA pool against
the indicated genes or control siRNA pool using Lipofectamine RNAiMAX reagent
according to the manufacturer’s instructions (Invitrogen). After 36–48 h transfec-
tion, cells were subjected to assays as indicated. The lentiviral shRNAs against
human and mouse Snail were cloned into pLKO.1 vector (Sigma, St Louis, MO),
and their sequences are listed in Supplementary Table 2. The Non-Target Control
shRNA (SHC002) and the lentiviral shRNA against human 4E-BP1 were from
Sigma. The specificity of the 4E-BP1 targeting sequence has been verified in our
previous study30. The lentiviral shRNAs against human Slug were obtained from
Addgene (10903; 10904). To establish stable transfectants with knockdown of
specific protein expression, cells were infected with lentivirus using the indicated
shRNA constructs followed by selection with puromycin (2 µg ml−1, for Snail and
Slug shRNAs) or hygromycin (250 µg ml−1, for 4E-BP1 shRNA) for 7–10 days30.
Generation of human Snail KO cell lines. Two small guide RNAs (sgRNAs) were
designed to target exon 1 of human Snail at two different sites using the CRISPR
designing tool59 and their sequences are listed in Supplementary Table 2. The
distance between target sites is roughly 50 bp. The two sgRNAs were cloned into
the Cas9 D10A nickase-coding pX462 vector (Addgene), and transiently co-
transfected into HCT116 and MDA-231 cells using Lipofectamine 3000 according
to the manufacturer’s protocol (Invitrogen). For Snail WT cells, HCT116 and
MDA-231 cells were transfected with non-sgRNA-Cas9 D10A nickase-encoding
pX462 vector. Single cells were selected by serial dilution followed by puromycin (2
µg ml−1) treatment for 1 week. Single-cell colonies were screened for internal
deletion by sequencing the PCR fragments using the following primers: 5′-
CCCAGTGATGTGCGTTTCCC-3′ (forward) and 5′- CCCAACCACCCAGACA-
GATC-3′ (reverse).
Quantitative real-time PCR analysis. Total cellular RNA was isolated using the
RNeasy plus mini kit (Qiagen, Valencia, CA). Equal amounts of RNA were used as
templates for all reactions. Complementary DNA was generated with the Super-
Script III First Strand Synthesis System (Invitrogen). Real-time PCR was performed
on a StepOne Real-Time PCR system (Applied Biosystems, Foster City, CA) in
triplicate with Maxima SYBR Green/ROX qPCR Master Mix (ThermoFisher Sci-
entific, Waltham, MA). The PCR primers used are listed in Supplementary Table 3.
Glyceraldehyde 3-phosphate dehydrogenase was used as an internal control for
normalization and relative expression level was calculated by the comparative CT
(ΔΔCT) method. Each experiment was performed in triplicate and repeated at least
three times.
4E-BP1 promoter reporter assay. Cells (1 × 105) were co-transfected with 0.5 µg
of the 4E-BP1 promoter or its mutant construct together with 0.1 µg of pHRL-TK
Renilla luciferase control vector using Lipofectamine 3000 according to the man-
ufacturer’s protocol (Invitrogen). Thirty-six hours post transfection, firefly and
Renilla luciferase activities were measured using a dual-luciferase assay kit (Pro-
mega). The firefly luciferase activity for each sample was normalized based on
transfection efficiency as determined by Renilla luciferase activity. Each experiment
was performed in triplicate and repeated at least three times.
ChIP assay. ChIP assay was performed according to the protocol described by
Nowak et al.60 with some modifications. Cells (4–6 × 106) were cross-linked with
1% formaldehyde for 15 min at room temperature, then lysed in L1 buffer (50 mM
Tris-HCl, pH 8.0, 2 mM EDTA, 0.1% IGEPAL, 10% glycerol, 1 mM dithiothreitol
(DTT), 1 mM phenylmethylsulfonyl fluoride, and protease inhibitor cocktail) on
ice. Nuclei were pelleted by centrifugation and resuspended in ChIP lysis buffer
(50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 1% SDS). Chromatin was subjected to
sonication and then immunoprecipitated with 2 µg of Snail antibody (AF3639,
R&D Systems, Minneapolis, MN) or an irrelevant immunoglobulin G (IgG)
overnight, followed by incubation with a 50% slurry of protein G sepharose/salmon
sperm DNA (Invitrogen) for 3 h at 4 °C. Bound DNA–protein complexes were
eluted, and crosslinks were reversed after a series of washes. Purified DNA was
resuspended in TE buffer (10 mM Tris–HCl, pH 8.0, 1 mM EDTA) for PCR
analysis. The primers used for the 4E-BP1 and E-cadherin promoters are listed in
Supplementary Table 4.
Cap-dependent translation assay. Cells (8 × 104) were transfected with a bicis-
tronic luciferase reporter plasmid (0.2 µg), pcDNA3-rLuc-PolioIRES-fLuc, which
directs cap-dependent translation of the Renilla luciferase gene and cap-
independent Polio IRES-mediated translation of the firefly luciferase gene29. After
24 h transfection, cells were treated with AZD8055 or INK128 for 12 h and cell
lysates were assayed for Renilla and firefly luciferase activities using a dual-
luciferase assay kit (Promega). Cap-dependent Renilla luciferase activity was nor-
malized against cap-independent firefly luciferase activity as the internal control.
The ratio of Renilla/firefly luciferase activity was calculated for cap-dependent
translational activity28,29. Each experiment was performed in triplicate and repe-
ated at least three times.
Immunoprecipitation and western blot analysis. Cells were lysed in NP-40 lysis
buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 10%
glycerol, protease, and phosphatase inhibitor cocktail). The cell lysates (250 µg
protein) were immunoprecipitated with 1 µg of eIF4E antibody (sc-271480, Santa
Cruz Biotechnology, Dallas, TX) overnight followed by incubation with a 50%
slurry of protein G sepharose beads for 3 h at 4 °C. The beads were washed three
times with the lysis buffer and the immunoprecipitated protein complexes were
resuspended in 2× Laemmli sample buffer followed by western blot analysis.
Western blot analysis were performed using equivalent total protein loadings as
described previously29. Antibodies for p-Akt (Ser473) (#4060; 1: 1000), p-p70S6
Kinase (Thr389) (#9234; 1: 1000), p-S6 (Ser235/236) (#4858; 1: 1000), p-4E-BP1
(Thr37/46) (#2855; 1: 1000), p-4E-BP1 (Ser65) (#13443; 1: 1000), p-4E-BP1
(Thr70) (#13396; 1: 1000), 4E-BP1 (#9644; 1: 1000), eIF4E (#2067; 1: 1000), Snail
(#3879; 1: 1000), Slug (#9585; 1: 1000), and Zeb1 (#3396; 1: 1000) were from Cell
Signaling Technology (Danvers, MA). Cyclins D1 (sc-718; 1: 1000), D2 (sc-181; 1:
500) and D3 (sc-182; 1: 1000), Twist (sc-81417; 1: 50), PTEN (sc-7974; 1: 500),
eIF4G (sc-133155; 1: 1000), and eIF4A (sc-377315; 1: 1000) antibodies were from
Santa Cruz Biotechnology. E-cadherin antibody (#610181; 1: 20,000) was from BD
Biosciences (San Jose, CA) and β-actin antibody (A5411; 1: 10,000) was from
Sigma. Uncropped scans of the most important western blottings are shown in
Supplementary Fig. 13.
Cap-binding assay. Cap-binding assay was performed as described previously29.
Briefly, cell lysates (500 µg protein) as prepared in the NP-40 lysis buffer were
incubated at 4 °C overnight with m7GTP Sepharose beads (GE Healthcare Life
Sciences, Pittsburgh, PA) to capture eIF4E and its binding partners. Precipitates
were washed three times with the lysis buffer and resuspended in 2× Laemmli
sample buffer followed by western blot analysis.
Polysome analysis. Polysome analysis was performed as described previously29
with some modifications. Sucrose density gradient centrifugation was employed to
separate the ribosome fractions following treatment of cells with drugs. 15 min
before collection, cycloheximide (100 µg ml−1) was added to the culture medium.
Cells were washed in ice-cold phosphate-buffered saline (PBS) containing 100 µg
ml−1 cycloheximide and collected in polysome lysis buffer (5 mM Tris-HCl, pH 7.5,
2.5 mM MgCl2, 1.5 mM KCl, 2 mM DTT, 0.5% Triton X-100, 0.5% sodium
deoxycholate, 100 µg ml−1 cycloheximide, 200 Uml−1 RNAsin, 0.2 mgml−1
heparin, and protease inhibitors). Cells were incubated on ice for 15 min and then
centrifuged at 10,000 × g for 10 min at 4 °C. The supernatant (4 mg protein) was
layered on a pre-chilled 10–50% linear sucrose gradient preparing in the gradient
buffer (5 mM Tris-HCl, pH 7.5, 2.5 mM MgCl2, 1.5 mM KCl, 2 mM DTT, 100 µg
ml−1 cycloheximide, 40 Uml−1 RNAsin, 0.1 mgml−1 heparin, and protease inhi-
bitors), and then centrifuged in a Beckman SW40Ti rotor at 250,000 × g for 2.5 h at
4 °C. Gradients were fractionated, while monitoring absorbance at A254 with a
Gradient Station System (Biocomp, Fredericton, NB, Canada).
Protein synthesis assay. To determine nascent protein synthesis, Click-iT AHA
(L-azidohomoalaine), Alexa Fluor 488 alkyne, and Click-iT cell reaction buffer kit
were purchased from Invitrogen and used according to the manufacturer’s pro-
tocol. Briefly, Click-iT AHA (50 µM), a methionine analog containing an azide
moiety, was added to cells in methionine-free medium (Invitrogen) for 1 h. The
cells were washed twice with PBS, fixed with 4% paraformaldehyde, and permea-
bilize with 0.25% Triton X-100. Detection of the incorporated amino acid utilizes a
click reaction between an azide and alkyne, where the azido-modified protein is
detected with an Alexa Fluor® 488 by flow cytometry.
Cell growth and proliferation assays. Cell growth was assessed as described
previously30. Briefly, 5 × 104 cells were seeded in six-well plates in triplicate. After
24 h, cells were treated with the indicated drugs and incubated at 37 °C. The cells
were cultured for 3 days and the number of viable cells was counted using the Vi-
CELL XR 2.03 (Beckman Coulter, Brea, CA). Cell proliferation was determined by
incorporation of EdU (5-ethynyl-2′-deoxyuridine) during DNA synthesis using a
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Click-iT EdU imaging kit according to the manufacturer’s protocol (Invitrogen).
Each experiment was performed in triplicate and repeated at least three times.
Colony formation assay. Cells were seeded in 12-well plates at 500 cells per well,
followed by the treatment with the indicated drugs the next day. Fresh culture
medium containing the corresponding concentrations of the drugs or dimethyl
sulfoxide (DMSO) vehicle control was added every 3 days. After 12 days of
treatment, the medium was removed, and cell colonies were fixed with 4% par-
aformaldehyde and stained with 0.1% crystal violet.
Cell cycle and apoptosis analysis. Cells were plated in 100 mm dishes. After 24 h,
cells were treated as indicated in figure legends; both adherent and floating cells
were collected. For cell cycle analysis, cell nuclei were prepared by the method of
Nusse61 and stained with ethidium bromide62. Cell cycle phase distribution was
determined by flow cytometry. For apoptosis, cells were analyzed by flow cyto-
metry using the Annexin V-APC Apoptosis Detection Kit according to the man-
ufacturer’s protocol (ThermoFisher Scientific).
Immunohistochemical staining. Paraffin-embedded colorectal cancer tissue sec-
tions were obtained from the tissue bank of Nanfang Hospital at Southern Medical
University in China. The tissue sections were deparaffinized, rehydrated and
treated with hydrogen peroxide. Antigen retrieval was performed using citrate
buffer (pH 6.0) in a steamer. Tissue sections were first blocked with avidin, biotin,
and 5% normal goat serum and then incubated in a humidified chamber at 4 °C
overnight with antibodies against Snail (NBP1-19529; 1: 100; Novus Biologicals,
Littleton, CO) or 4E-BP1 (#9644; 1: 2,000; Cell Signaling Technology). The samples
were then incubated with biotin-labeled goat anti-rabbit secondary antibody and
subsequently with horseradish peroxidase–avidin complex (Vector Laboratories,
Burlingame, CA). Antibody-associated staining was visualized using diamino-
benzidine substrate solution and the tissue sections were then counterstained with
hematoxylin. The immunoreactivity was scored blindly according to the value of
immunoreaction intensity and the percentage of tumor cell staining using a semi-
quantitative seven-tier system63,64.
Animal studies. Male athymic nude mice (5–6 weeks old) were purchased from
Taconic (Hudson, NY), and maintained and treated under specific pathogen-free
conditions. Experiments were carried out under a protocol approved by the Uni-
versity of Kentucky Institutional Animal Care and Use Committee. HCT116
xenograft tumors were established by subcutaneously injecting HCT116 cells (3 ×
106 per mouse) in a 1: 1 mixture of media and Matrigel (BD Biosciences). Mice
were randomized among control and treated groups (n = 6 per group) when
tumors were well-established (~150–180 mm3). INK128 was formulated in 5% N-
methyl-2-pyrrolidone plus 15% polyvinylpyrrolidone as described10 and delivered
orally at 1.5 mg kg−1 once or twice per day for 5 consecutive days each week.
Vorinostat was dissolved in DMSO and diluted in 1: 1 PEG400 and sterile water to
a final composition of 10% DMSO, 45% PEG400, and 45% water as described65.
Vorinostat was administered intraperitoneally at 50 mg kg−1 once per day for 5
consecutive days each week. For combination treatment, both drugs were given
concurrently. Control mice received vehicle alone for both drugs. Tumor dimen-
sions were measured using a caliper and tumor volumes were calculated as mm3 =
π/6 x larger diameter x (smaller diameter)2. Tumors were excised and snap frozen
in liquid nitrogen, homogenized in 2% SDS lysis buffer, and then processed for
western blot analysis29,30.
Statistical analysis. Statistical analyses for each experiment were performed as
described in the corresponding figure legends. Data between groups were com-
pared using a two-tailed unpaired Student’s t-test, χ2-test, or Mann–Whitney test.
All data are presented as mean±SEM, if not stated otherwise. Differences between
groups were considered statistically significant at P< 0.05. Data presented is
representative of two or more independent experiments, unless indicated
otherwise.
Data availability. All data generated or analyzed during this study are available
within the Article and Supplementary Files, or available from the corresponding
author upon reasonable request.
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